Eli Lilly and Company has opened a new research and development facility in the Boston Seaport dedicated to RNA and DNA-based therapies as well as for discovering new drug targets across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. 

The facility occupies 346,000 square feet in a 12-story building in the Seaport District of Boston. The new site includes laboratories and office space. It will accommodate approximately 500 Lilly scientists and researchers in addition to 200 people from the companies within Lilly Gateway Labs, an innovation hub between early-stage biotechs and Lilly. The new Boston site will house the first Lilly Gateway Labs location on the East Coast in the US.  

Since opening in December 2019, Lilly Gateway Labs in San Francisco has hosted over 20 biotech companies, with more than 50 therapeutics and platforms currently in development, and more than $1 billion raised by partner companies. In 2024, Lilly Gateway Labs is expanding to four sites across San Francisco, San Diego, and this new site in Boston.  

Source: Eli Lilly and Company